Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted therapy for adolescents with treatment-resistant PTSD
2024-515184-65-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Amsterdam University Medical Center. Primary endpoints: Treatment completion (feasibility) and Safety (adverse events). Planned start Aug 2026; status: authorised.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2024-515184-65-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515184-65-01.